Skip to Content

Dopamine Hydrochloride

Pronunciation

Class: Selective beta-1-Adrenergic Agonists
VA Class: AU100
CAS Number: 62-31-7

Warning(s)

  • Extravasation Risk
  • Phentolamine is the local antidote for peripheral ischemia resulting from extravasation of dopamine.115 116

  • Phentolamine should be given as soon as possible after extravasation is noted.115 116

  • Infiltrate the affected area (using a syringe with a fine hypodermic needle) liberally throughout as soon as possible with 10–15 mL of 0.9% sodium chloride injection containing 5–10 mg of phentolamine mesylate (an α-adrenergic blocking agent) to prevent sloughing and necrosis in ischemic areas.115 116

  • In children, phentolamine mesylate doses of 0.1–0.2 mg/kg (maximum: 10 mg per dose) may be infiltrated.116

  • Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.115 116

Introduction

Dopamine, an endogenous catecholamine that is the immediate precursor of norepinephrine, is a sympathomimetic agent with prominent dopaminergic and β1-adrenergic effects at low to moderate doses and α-adrenergic effects at high doses.112 115

Uses for Dopamine Hydrochloride

Shock

Used as adjunctive therapy to correct hemodynamic imbalances (e.g., increase cardiac output and BP) in the treatment of shock.100 112 115

Pressor therapy is not a substitute for replacement of blood, plasma, fluids, and/or electrolytes.b Correct blood volume depletion as fully as possible before administration.b

Norepinephrine is considered drug of choice when a vasopressor is indicated in patients with septic shock; although dopamine was used widely in the past, more recent evidence indicates that the drug is associated with a greater risk of adverse effects (e.g., arrhythmias) and possibly also an increased risk of death compared with norepinephrine.153 154 155 158 163 In current expert guidelines, dopamine is considered an alternative to norepinephrine only in highly selected patients with septic shock (e.g., those with low risk of tachyarrhythmias and bradycardia).153

Also used to provide vasopressor support in other types of shock (e.g., cardiogenic, hemorrhagic), generally as a temporary measure until underlying cause can be treated.152 157 158 159 160 161 162

Some evidence suggests that dopamine may be associated with increased risk of mortality compared with norepinephrine in patients with cardiogenic shock.115 154 161 162 Early revascularization is standard of care in patients with cardiogenic shock; individualize use of vasopressors in this setting.161 162

Some experts state dopamine may be considered for treatment of drug-induced hypovolemic shock when patient is unresponsive to fluid volume expansion and inotropic and/or vasopressor support is required.112

May increase cardiac output, BP, and urine flow in shock; however, exact effects are dose related and based on patient's clinical status at time of administration.115 In low or intermediate doses, usually does not produce sufficient peripheral vasoconstriction to increase BP.115 If hypotension persists, a more potent vasoconstrictor such as norepinephrine may be required.115

Appears to be most effective when therapy is begun shortly after the signs and symptoms of shock appear and before physiologic parameters such as BP and myocardial function undergo severe deterioration and before urine flow has decreased to <0.3 mL/minute.115

Advanced Cardiovascular Life Support

Used in ACLS for treatment of symptomatic bradycardia in adults, particularly if associated with hypotension; although not a first-line drug, may be considered in patients who are unresponsive to atropine, or as a temporizing measure while awaiting a pacemaker.400 401

Also used during resuscitation for management of patients in cardiac arrest.112 Principal goal of pharmacologic therapy during cardiac arrest is to facilitate the return of spontaneous circulation (ROSC), and epinephrine is the drug of choice for this use.400 401 Vasoactive drugs such as dopamine may be used for hemodynamic support following resuscitation.403 404

Acute Renal Failure

Low-dose (“renal dose,” e.g., <5 mcg/kg per minute) therapy does not appear to prevent or ameliorate acute (e.g., oliguric) renal failure in critically ill patients100 102 105 106 107 108 112 despite some evidence of increased renal and mesenteric perfusion from selective dopaminergic effects.107 109 110 Currently available data do not support any benefit from such therapy, and routine use of low-dose (“renal dose”) dopamine therapy for prevention or amelioration of acute renal failure in critically ill patients not recommended.102 105 106 107 108 112 153 156

In addition, low-dose dopamine infusions are not without risk and may be associated with adverse effects (e.g., suppression of respiratory drive,101 102 104 106 increased cardiac output and myocardial oxygen consumption,101 102 104 106 arrhythmias,101 102 104 106 hypokalemia,101 102 104 hypophosphatemia,101 102 104 gut ischemia,101 102 104 disruption of metabolic and immunologic homeostasis).101 102 104 107

Heart Failure

May be used for inotropic support in patients with refractory heart failure.165 Because parenteral inotropes can be potentially harmful (e.g., increased risk of arrhythmias) in patients with heart failure, some experts recommend that such use be reserved for patients with severe systolic dysfunction who have low cardiac index and evidence of systemic hypoperfusion and/or congestion, or for palliative therapy in those with end-stage heart failure.165 To minimize risk of adverse effects, use lowest possible dosage and evaluate regularly for need for continued inotropic therapy.165

Low-dose dopamine infusion has been used in combination with loop diuretics to augment diuresis and improve renal blood flow in patients with acute decompensated heart failure; however, current evidence does not support routine use of dopamine for this purpose.115 116 165 166 168 169 170 174

Dopamine Hydrochloride Dosage and Administration

Administration

Administer by IV infusion.115 116

Also has been administered by intraosseous infusion during ACLS.401 403

IV Infusion

For solution and drug compatibility information, see Compatibility under Stability.

Infuse IV into a large vein, preferably the antecubital vein, using an infusion pump or other apparatus to control the rate of flow and avoid inadvertent administration of a bolus dose.115 116

Use less suitable veins (e.g., hand or ankle vein) only when required, but switch to a preferred vein as soon as possible.115

Continuously monitor infusion site for free flow.115

Avoid extravasation.115 116 (See Boxed Warning and also see Extravasation under Cautions.)

A controlled-infusion device, preferably a volumetric pump, should be used; do not administer via an ordinary, gravity-controlled IV administration set.115 116

Dopamine in 5% dextrose in flexible containers (e.g., LifeCare) should not be used in series connections.116

Consult manufacturer's labeling for proper methods of administration and other associated precautions.115 116

Dilution

Must dilute the commercially available injection concentrate for IV infusion prior to administration;115 alternatively, may use commercially available prediluted solutions of dopamine hydrochloride in 5% dextrose.116

Individualize concentration according to patient dosage and fluid requirements.b Consult manufacturer's prescribing information for suggested dilutions.115

Rate of Administration

Avoid bolus administration.115

Rate of IV infusion varies according to individual dose requirements.115 116 (See Dosage under Dosage and Administration.)

Dosage

Individualize and carefully adjust dosage to achieve the desired hemodynamic and renal response as indicated by heart rate, BP, urine flow, and, whenever possible, measurement of central venous or pulmonary wedge pressure and cardiac output.115 116 Once optimal hemodynamic effects have been achieved, use lowest possible dosage to maintain these effects.b

When discontinuing therapy, it may be necessary to gradually decrease the dose while expanding blood volume with IV fluids to prevent a recurrence of hypotension.115 Sudden discontinuance can precipitate marked hypotension.b (See Hypotension under Cautions.) In patients who have been receiving moderate to high doses, some clinicians recommend that the final dosage should not be less than 5 mcg/kg per minute in order to avoid hypotension.b

Pediatric Patients

Shock
IV

Studies have not been conducted to specifically inform dosage recommendations in pediatric patients; however, clinical experience indicates that dosing in pediatric patients is generally similar to that in adults.115 116

ACLS
IV or Intraosseous

Usual infusion rate for postresuscitation stabilization is 2–20 mcg/kg per minute.403 Although dosages >5 mcg/kg per minute stimulate the cardiac β-adrenergic receptors, this effect may be reduced in infants.403 Infusion rates >20 mcg/kg per minute may result in excessive vasoconstriction.403

Adults

Shock
IV

Usually, initiate at a rate of 2–5 mcg/kg per minute;115 may increase by 1–4 mcg/kg per minute at 10- to 30-minute intervals until the optimal response is attained.b In more severely ill patients, initiate at 5 mcg/kg per minute, and gradually increase in increments of 5–10 mcg/kg per minute up to 20–50 mcg/kg per minute as needed.115

In patients with occlusive vascular disease, some experts recommend initial rate of ≤1 mcg/kg per minute because of risk of local ischemia (e.g., gangrene).59 Monitor closely for any signs or symptoms of compromised circulation; if this occurs, decrease rate or discontinue infusion.115

If MAO inhibitors were used within the previous 2–3 weeks, initiate dopamine at no greater than 10% of the usual dose.115 (See MAO Inhibitors under Cautions.)

Titrate dosage to achieve desired hemodynamic effects.115 Most patients can be maintained at <20 mcg/kg per minute; however, infusion rates >50 mcg/kg per minute have been used safely in advanced states of circulatory decompensation.115

ACLS
IV

Usual initial dosage range for symptomatic bradycardia is 2–10 mcg/kg per minute; titrate according to patient response.401 Infusion rates >10 mcg/kg per minute are associated with vasoconstrictive effects.401

For postresuscitation stabilization, dosage of 5–10 mcg/kg per minute has been recommended.404

Heart Failure
IV

Some clinicians recommend initial rate of 0.5–2 mcg/kg per minute in patients with severe, refractory heart failure.b Usual dosage range is 5–10 mcg/kg per minute.165

To minimize risk of adverse effects, use lowest possible dosage and evaluate patient regularly for the need for continued inotropic therapy.165

Special Populations

Hepatic Impairment

No specific dosage recommendations.115

Renal Impairment

No specific dosage recommendations.115

Geriatric Patients

Initial dosage usually should be at the low end of the range.116

Cautions for Dopamine Hydrochloride

Contraindications

  • Pheochromocytoma.115 116

  • Uncorrected tachyarrhythmias or VF.115 116

Warnings/Precautions

Warnings

MAO Inhibitors

Metabolized by MAO; therefore, inhibition of this enzyme prolongs duration of dopamine effects.115 Patients recently (within 2–3 weeks) treated with MAO inhibitors will require substantially reduced dopamine dosage.115 (See Dosage under Dosage and Administration.)

Alkalinizing Substances

Inactivated in alkaline solutions; do not administer with any alkaline diluent solution (e.g., sodium bicarbonate).115

Sensitivity Reactions

Sulfites

Some formulations contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.115 116

General Precautions

Monitoring

Monitor BP and urine flow and, when possible, cardiac output and pulmonary wedge pressure.115 116 (See Hypovolemia and also Hypoxia, Hypercapnia, and Acidosis under Cautions.) Decrease rate or temporarily interrupt infusion if excessive vasoconstriction, decreased urine output, increased heart rate, or an arrhythmia occurs and observe the patient closely.b

Extravasation

Extravasation may cause tissue necrosis and sloughing of surrounding tissues;115 avoid extravasation.115 Infuse IV into a large vein.115 (See Boxed Warning.)

Continuously monitor infusion site for free flow.115

Hypovolemia

Pressor therapy is not a substitute for replacement of blood, plasma, fluids, and/or electrolytes.b Correct blood volume depletion as fully as possible before dopamine therapy is instituted.b

May be used in an emergency as an adjunct to fluid replacement or as a temporary supportive measure to maintain coronary and cerebral artery perfusion until volume replacement can be completed, but dopamine must not be used as sole therapy in hypovolemic patients.b

Monitor central venous pressure or left ventricular filling pressure; in addition, monitor central venous or pulmonary arterial diastolic pressure to avoid overloading the cardiovascular system, diluting serum electrolyte concentrations, and precipitating congestive heart failure or pulmonary edema.b

Hypoxia, Hypercapnia, and Acidosis

Must be identified and corrected prior to, or concurrently with, dopamine administration.115 Can reduce the effectiveness and/or increase the toxicity of dopamine.115

Vasoconstriction

At high rates of infusion, vasoconstrictive effects of dopamine may cause compromised limb circulation and reversal of renal dilation and natriuresis.115

If a disproportionate increase in diastolic pressure occurs, decrease rate of infusion and observe the patient carefully for further evidence of predominant vasoconstrictor activity, unless such an effect is desired.115

Hypotension

If hypotension occurs, infusion rate should be increased rapidly in order to increase BP.115 If hypotension persists, discontinue dopamine and administer a drug with greater vasoconstricting properties (e.g., norepinephrine).115

Occlusive Vascular Disease

Carefully monitor patients with a history of occlusive vascular disease (e.g., atherosclerosis, arterial embolism, Raynaud’s disease, cold injury, diabetic endarteritis, or Buerger’s disease) for decreased circulation to the extremities indicated by changes in color or temperature of the skin or pain in the extremities.115

Correct by decreasing the rate of infusion or discontinuing dopamine;115 however, these changes occasionally have persisted and progressed after discontinuing the drug.b

Some clinicians recommend IV administration of 5–10 mg of phentolamine mesylate if discoloration of the extremities occurs.b

Weigh potential benefits of continuing dopamine against possible risk of necrosis.b

Ventricular Arrhythmias

Ventricular arrhythmias may occur; monitor patient and reduce dosage if increased number of ectopic beats observed.115

Specific Populations

Pregnancy

Category C.116

No adequate and well-controlled studies in pregnant women; use during pregnancy only when potential benefits justify potential risks to fetus.115

When used in ACLS, may decrease blood flow to uterus; however, the woman must be resuscitated for survival of the fetus.112

If a vasopressor (e.g., dopamine) is used during labor in conjunction with oxytocic drugs, the vasopressor effect may be potentiated and result in severe hypertension.b (See Specific Drugs and Laboratory Tests under Interactions.)

Lactation

Not known whether dopamine is distributed into human milk.115 Caution if used in nursing women.115

Pediatric Use

Manufacturer states safety and efficacy of IV dopamine not established in children;115 however, the drug has been used in pediatric patients of all age groups from neonate onward.116

Except for vasoconstrictive effects caused by inadvertent infusion of dopamine into the umbilical artery, adverse effects unique to the pediatric population have not been identified, nor have adverse effects identified in adults been found to be more common in pediatric patients.116

Has been administered at rates as high as 125 mcg/kg per minute in some neonates, but the usual dosage in children has been similar to that in adults on a mcg/kg per minute basis.116

In pediatric patients, dopamine is recommended as an appropriate drug for the treatment of shock that is unresponsive to fluids when systemic vascular resistance is low.403

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.116

No differences in responses between geriatric and younger patients have been identified.116

Initial usual dosage should be at the low end of the dosage range, and caution should be exercised since renal, hepatic, and cardiovascular dysfunction and concomitant disease or other drug therapy are more common in this age group than in younger adults.116

Common Adverse Effects

Dopamine may cause cardiac conduction abnormalities (e.g., ventricular arrhythmia, atrial fibrillation, widened QRS complex, ectopic heartbeats), tachycardia, angina, palpitation, bradycardia, vasoconstriction, hypotension, hypertension, dyspnea, nausea, vomiting, headache, anxiety, azotemia, piloerection, and gangrene of the extremities.115

Interactions for Dopamine Hydrochloride

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Comments

α-Adrenergic blocking agents

Antagonizes peripheral vasoconstriction caused by high dopamine doses115

β-Adrenergic blocking agents (e.g., metoprolol, propranolol)

Cardiac effects of dopamine are antagonized115

Anesthetics, general (cyclopropane, halogenated hydrocarbons)

May increase cardiac irritability, resulting in ventricular arrhythmias and hypertension with usual dopamine doses during halogenated hydrocarbon (e.g., halothane) or cyclopropane anesthesia115

Extreme caution115

Antidepressants, tricyclic

May potentiate pressor response of dopamine115

Butyrophenones (e.g., haloperidol)

Can suppress the dopaminergic renal and mesenteric vasodilation induced with low-dose dopamine115 116

Diuretics (e.g., hydrochlorothiazide, furosemide)

Diuretic effects (on urine flow) of low dopamine dosages may be additive with or potentiated by diuretics115

Growth hormone (somatropin)

Suppresses pituitary secretion116

MAO inhibitors

Inhibits dopamine metabolism; dopamine effects are prolonged and intensified by MAO inhibitors115

Reduce initial dopamine dosage (dosages no greater than 10% of usual) if MAO inhibitors were used within the previous 2–3 weeks115

Phenytoin

Potential hypotension and bradycardia115

Consider alternative anticonvulsant therapy115

Prolactin

Suppresses pituitary secretion116

Oxytocics

Pressor effect may be potentiated with resultant severe hypertension115

Phenothiazines

Can suppress the dopaminergic renal and mesenteric vasodilation induced with low-dose dopamine infusion115 116

Thyrotropin (thyroid-stimulating hormone, TSH)

Suppresses pituitary secretion116

Vasopressors or vasoconstrictors (e.g., ergonovine)

Concomitant use may result in severe hypertension116

Dopamine Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Rapidly metabolized in the GI tract after oral administration.b

Onset

Within 5 minutes following IV administration.b

Duration

<10 minutes.b

Distribution

Extent

Widely distributed but does not cross the blood-brain barrier to a substantial extent.b

Apparent volume of distribution in neonates ranges from 0.6–4 L/kg.b

Not known whether dopamine crosses the placenta or is distributed into milk.b

Elimination

Metabolism

Via the liver, kidneys, and plasma by MAO and catechol-O-methyltransferase (COMT) to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid.b

In patients receiving MAO inhibitors, the duration of action of dopamine may be as long as 1 hour.b

About 25% of a dose of dopamine is metabolized to norepinephrine within the adrenergic nerve terminals.b

Elimination Route

In urine principally as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid; a very small fraction of a dose is excreted unchanged.b

Half-life

Plasma half-life: About 2 minutes.b

Special Populations

Neonates: Elimination half-life of 5–11 minutes.b

Critically ill infants and children: Clearance reportedly ranges from 48–168 mL/kg per minute, with the higher values reported in the younger patients.b

Stability

Storage

Parenteral

Injection Concentrate for IV Infusion

20–25°C.115

Injection for IV Infusion

20–25°C.116 Do not freeze.116

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Incompatible with sodium bicarbonate and other alkaline solutions.100 HID

Avoid contact with oxidizing agents and iron salts.115

Solution CompatibilityHID

Stable for at least 24 hours in dextrose 5%, dextrose 5% in sodium chloride 0.9%, dextrose 5% in sodium chloride 0.45%, dextrose 5% in lactated Ringer’s injection, lactated Ringer's, 0.9% sodium chloride, and sodium lactate (1/6)M.115

Compatible

Amino acids 4.25%, dextrose 25%

Dextrose 5% in Ringer’s injection, lactated

Dextrose 5% in sodium chloride 0.45 or 0.9%

Dextrose 10% in sodium chloride 0.18%

Dextrose 5 or 10% in water

Mannitol 20% in water

Ringer’s injection, lactated

Sodium chloride 0.9%

Sodium lactate (1/6) M

Incompatible

Sodium bicarbonate 5%

Drug Compatibility

Additives should not be introduced into the infusion container (e.g., LifeCare ) of commercially available premixed solutions for IV infusion.116

Admixture CompatibilityHID

Compatible

Aminophylline

Atracurium besylate

Calcium chloride

Chloramphenicol sodium succinate

Ciprofloxacin

Dobutamine HCl

Enalaprilat

Flumazenil

Heparin sodium

Hydrocortisone sodium succinate

Lidocaine HCl

Meropenem

Methylprednisolone sodium succinate

Nitroglycerin

Oxacillin sodium

Potassium chloride

Ranitidine HCl

Verapamil HCl

Incompatible

Acyclovir sodium

Alteplase

Amphotericin B

Ampicillin sodium

Penicillin G potassium

Sodium bicarbonate100

Variable

Gentamicin sulfate

Y-Site CompatibilityHID

Compatible

Alprostadil

Amifostine

Amiodarone HCl

Anidulafungin

Argatroban

Atracurium besylate

Aztreonam

Bivalirudin

Caffeine citrate

Caspofungin acetate

Cefepime HCl

Ceftaroline fosamil

Ceftazidime

Ciprofloxacin

Cisatracurium besylate

Cladribine

Clarithromycin

Clonidine HCl

Daptomycin

Dexmedetomidine HCl

Diltiazem HCl

Dobutamine HCl

Dobutamine HCl with lidocaine HCl

Dobutamine HCl with nitroglycerin

Dobutamine HCl with sodium nitroprusside

Docetaxel

Doripenem

Doxorubicin HCl liposome injection

Enalaprilat

Epinephrine HCl

Esmolol HCl

Etoposide phosphate

Famotidine

Fenoldopam mesylate

Fentanyl citrate

Fluconazole

Foscarnet sodium

Gemcitabine HCl

Granisetron HCl

Haloperidol lactate

Heparin sodium

Hetastarch in lactated electrolyte injection (Hextend)

Hydrocortisone sodium succinate

Hydromorphone HCl

Hydroxyethyl starch 130/0.4 in sodium chloride 0.9%

Labetalol HCl

Levofloxacin

Lidocaine HCl

Lidocaine HCl with dobutamine HCl

Lidocaine HCl with nitroglycerin

Lidocaine HCl with sodium nitroprusside

Linezolid

Lorazepam

Meperidine HCl

Methylprednisolone sodium succinate

Metronidazole

Micafungin sodium

Midazolam HCl

Milrinone lactate

Morphine sulfate

Mycophenolate mofetil HCl

Nicardipine HCl

Nitroglycerin

Nitroglycerin with dobutamine HCl

Nitroglycerin with lidocaine HCl

Nitroglycerin with sodium nitroprusside

Norepinephrine bitartrate

Ondansetron HCl

Oxaliplatin

Pancuronium bromide

Pantoprazole sodium

Pemetrexed disodium

Piperacillin sodium–tazobactam sodium

Potassium chloride

Propofol

Ranitidine HCl

Remifentanil HCl

Sargramostim

Sodium nitroprusside

Sodium nitroprusside with dobutamine HCl

Sodium nitroprusside with lidocaine HCl

Sodium nitroprusside with nitroglycerin

Tacrolimus

Telavancin HCl

Theophylline

Thiotepa

Tigecycline

Tirofiban HCl

Vasopressin

Vecuronium bromide

Verapamil HCl

Warfarin sodium

Zidovudine

Incompatible

Acyclovir sodium

Alteplase

Amphotericin B cholesteryl sulfate complex

Indomethacin sodium trihydrate

Insulin, regular

Sodium bicarbonateb

Variable

Aldesleukin

Furosemide

Actions

  • Stimulates adrenergic receptors of the sympathetic nervous system.b 112

  • Principally a direct stimulatory effect on β1-adrenergic receptors.b

  • Acts on specific dopaminergic receptors in the renal, mesenteric, coronary, and intracerebral vascular beds to cause vasodilation.b

  • Little or no effect on β2-adrenergic receptors.b

  • Main effects depend on the dose administered.115 b

  • In low doses (0.5–2 mcg/kg per minute), acts predominantly on dopaminergic receptors causing vasodilation in renal, mesenteric, coronary, and intracerebral vascular beds.112 115 Renal vasodilation results in increased renal blood flow, urine flow, and GFR.115

  • At intermediate doses (2–10 mcg/kg per minute), stimulates β1-adrenergic receptors, resulting in improved myocardial contractility; blood flow to peripheral vascular beds may decrease while mesenteric blood flow is increased because of increased cardiac output.115

  • At doses of 10–20 mcg/kg per minute, α-adrenergic receptors are stimulated with consequent vasoconstrictor effects and an increase in BP.115

  • At doses >20 mcg/kg per minute, α-adrenergic effects become more prominent compromising peripheral circulation and overriding the drug's dopaminergic effects; renal vasoconstriction may decrease previously augmented renal blood flow and urine output.115 b

Advice to Patients

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.115 116

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.115 116

  • Importance of informing patients of other important precautionary information.115 116 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Dopamine Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Concentrate, for injection, for IV infusion

40 mg/mL*

Dopamine Hydrochloride Injection

80 mg/mL*

Dopamine Hydrochloride Injection

160 mg/mL*

Dopamine Hydrochloride Injection

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Dopamine Hydrochloride in Dextrose

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

Injection, for IV infusion

0.8 mg/mL Dopamine Hydrochloride (200 or 400 mg) in Dextrose 5%*

0.08% Dopamine Hydrochloride in 5% Dextrose Injection (LifeCare, Viaflex Plus)

1.6 mg/mL Dopamine Hydrochloride (400 or 800 mg) in Dextrose 5%*

0.16% Dopamine Hydrochloride in 5% Dextrose Injection (LifeCare, Viaflex Plus)

3.2 mg/mL Dopamine Hydrochloride (800 mg) in Dextrose 5%*

0.32% Dopamine Hydrochloride in 5% Dextrose Injection (LifeCare, Viaflex Plus)

AHFS DI Essentials. © Copyright, 2004-2016, Selected Revisions June 29, 2016. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

59. Alexander CS, Sako Y, Mikulic E. Pedal gangrene associated with the use of dopamine. N Engl J Med. 1975; 293:591. [PubMed 1152894]

100. The American Heart Association in Collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2000; 102(Suppl I) I-131-2, I-189, I-328-9.

101. Bellomo R, Chapman M, Finfer S et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000; 356:2139-43. [IDIS 457742] [PubMed 11191541]

102. Galley HF. Renal-dose dopamine: will the message now get through? Lancet. 2000; 356:2112-3.

103. Juste RN, Moran L, Hooper J et al. Dopamine clearance in critically ill patients. Intensive Care Med. 1998; 24:1217-20. [IDIS 421445] [PubMed 9876986]

104. Corwin HL, Lisbon A. Renal dose dopamine: long on conjecture, short on fact. Crit Care Med. 2000; 28:1657-8. [IDIS 448836] [PubMed 10834734]

105. Marik PE, Iglesias J, et al. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. Am J Med. 1999; 107:387-90. [IDIS 437296] [PubMed 10527041]

106. Horan JL, Bobek MB, Arroliga AC. Acute renal failure: overview of current and potential therapies. Formulary. 2000; 35:669-80.

107. Mueller BA, Macias WL. Acute Renal Failure. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford: Appleton and Lange; 1999:706-31.

108. Dishart MK, Kellum JA. An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs. 2000; 59:79-91. [PubMed 10718100]

109. Ichai C, Soubielle J, Carles M et al. Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: a single-blind randomized study. Crit Care Med. 2000; 28:921-8. [IDIS 447545] [PubMed 10809260]

110. Ichai C, Passeron C, Carles M et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: a single-blind, prospective, controlled study. Crit Care Med. 2000; 28:1329-35. [IDIS 448826] [PubMed 10834674]

111. Vovan T, Brenner M. Controversy: is there a “renal dose” dopamine? Crit Care Med. 2000; 28:1220. Editorial.

112. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I): IV1-211.

115. Hospira. Dopamine hydrochloride prescribing information. Lake Forest, IL; 2014 Mar.

116. Hospira. Dopamine hydrochloride and 5% dextrose injection prescribing information. Lake Forest, IL; 2014 May.

152. Spahn DR, Bouillon B, Cerny V et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013; 17:R76. [PubMed 23601765]

153. Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39:165-228. [PubMed 23361625]

154. De Backer D, Biston P, Devriendt J et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362:779-89. [PubMed 20200382]

155. Cawcutt KA, Peters SG. Severe sepsis and septic shock: clinical overview and update on management. Mayo Clin Proc. 2014; 89:1572-8. [PubMed 25444488]

156. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2014; 370:583. [PubMed 24499231]

157. Bouglé A, Harrois A, Duranteau J. Resuscitative strategies in traumatic hemorrhagic shock. Ann Intensive Care. 2013; 3:1. [PubMed 23311726]

158. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011; 183:847-55. [PubMed 21097695]

159. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008; 117:686-97. [PubMed 18250279]

160. Sperry JL, Minei JP, Frankel HL et al. Early use of vasopressors after injury: caution before constriction. J Trauma. 2008; 64:9-14. [PubMed 18188092]

161. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O'Gara PT et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61:e78-140. [PubMed 23256914]

162. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64:e139-228. [PubMed 25260718]

163. Gamper G, Havel C, Arrich J et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016; 2:CD003709. [PubMed 26878401]

165. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327. [PubMed 23741058]

166. Cicci JD, Reed BN, McNeely EB et al. Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34:373-88. [PubMed 24214219]

167. Giamouzis G, Butler J, Starling RC et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010; 16(12):922-30.

168. Triposkiadis FK, Butler J, Karayannis G et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014;172(1):115-21.

169. Torres-Courchoud I, Chen HH. Is there still a role for low-dose dopamine use in acute heart failure?. Curr Opin Crit Care. 2014; 20:467-71. [PubMed 25137402]

170. Houston BA, Kalathiya RJ, Kim DA et al. Volume Overload in Heart Failure: An Evidence-Based Review of Strategies for Treatment and Prevention. Mayo Clin Proc. 2015; 90:1247-61. [PubMed 26189443]

174. Chen HH, Anstrom KJ, Givertz MM et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013; 310:2533-43. [PubMed 24247300]

400. Link MS, Berkow LC, Kudenchuk PJ et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132(18 Suppl 2):S444-64. [PubMed 26472995]

401. Neumar RW, Otto CW, Link MS et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18 Suppl 3):S729-67. [PubMed 20956224]

403. Kleinman ME, Chameides L, Schexnayder SM et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18 Suppl 3):S876-908. [PubMed 20956230]

404. Peberdy MA, Callaway CW, Neumar RW et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18 Suppl 3):S768-86. [PubMed 20956225]

pdh. Schilling McCann JA, Publisher. Pharmacists drug handbook. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins and American Society of Health-System Pharmacists; 2003.

HID. McEvoy GK, ed. Handbook on injectable drugs. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2015:449-50..

b. AHFS drug information 2017. McEvoy GK, ed. Dopamine. Bethesda, MD: American Society of Health-System Pharmacists; 2017

Hide